- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00528424
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease
Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857 (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less, the cord affecting that joint received less than three injections of AA4500, or they had other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option to receive up to five injections of AA4500 in this extension study. Subjects requiring further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each injection, with injections separated by four weeks. Follow-up visits for the determination of efficacy and safety were conducted on Day 90, Month 6, and Month 9.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- 100 UCLA Medical Plaza, Suite 305
-
Palo Alto, California, Estados Unidos, 94304
- Hand Surgery Clinic
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80210
- Hand Surgery Associates, PC
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- The Hand and Upper Extremity Center of Georgia, P.C.
-
-
Illinois
-
Rockford, Illinois, Estados Unidos, 61107
- Rockford Orthopedic Associates, Ltd.
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- The Indiana Hand Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham and Women's Hospital, Department of Orthopedic Surgery
-
Newton, Massachusetts, Estados Unidos, 02462
- Newton-Wellesley Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55431
- TRIA Orthopaedic Center
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Hospital for Special Surgery
-
Stony Brook, New York, Estados Unidos, 11794
- SUNY Stony Brook - Department of Orthopedics
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73109
- Health Research Institute
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16550
- Hand Microsurgery & Reconstructive Orthopaedics
-
State College, Pennsylvania, Estados Unidos, 16801
- University Orthopedics Center
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02905
- Department of Orthopaedics, Brown University, Rhode Island Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
- Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
- Were naïve to AA4500 treatment or had received only one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).
- Were judged to be in good health.
- Must have participated in protocol AUX-CC-857 (NCT00528606).
Exclusion Criteria:
- Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
- Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
- Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: AA4500 0,58 mg
|
Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days.
Individual cords may have received up to a maximum of three AA4500 injections.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Reduction in Contracture to 5° or Less
Periodo de tiempo: Within 30 days after last injection
|
Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
|
Within 30 days after last injection
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Clinical Improvement After the Last Injection
Periodo de tiempo: Baseline, within 30 days after last injection
|
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
|
Baseline, within 30 days after last injection
|
Percent Reduction From Baseline Contracture After the Last Injection
Periodo de tiempo: Baseline, Day 30 after last injection
|
Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture - last available post-injection contracture)/baseline contracture.
|
Baseline, Day 30 after last injection
|
Change From Baseline Range of Motion After the Last Injection
Periodo de tiempo: Baseline, Day 30 after last injection
|
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
|
Baseline, Day 30 after last injection
|
Time to Reach Clinical Success
Periodo de tiempo: Within 30 days after last injection
|
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories
|
Within 30 days after last injection
|
Clinical Success After the First Injection
Periodo de tiempo: Within 30 days after first injection
|
Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.
|
Within 30 days after first injection
|
Clinical Improvement After the First Injection
Periodo de tiempo: Baseline, within 30 days after first injection
|
Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection
|
Baseline, within 30 days after first injection
|
Percent Reduction From Baseline Contracture After the First Injection
Periodo de tiempo: Baseline, Day 30 after first injection
|
Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture - last available post-injection contracture)/baseline contracture.
|
Baseline, Day 30 after first injection
|
Change From Baseline Range of Motion After the First Injection
Periodo de tiempo: Baseline, Day 30 after first injection
|
Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion
|
Baseline, Day 30 after first injection
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Veronica Urdaneta, MD, Endo Pharmaceuticals
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- AUX-CC-858
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Dupuytren avanzada
-
Advanced BionicsTerminadoPérdida auditiva severa a profunda | en usuarios adultos de Advanced Bionics HiResolution™ Bionic Ear SystemEstados Unidos
Ensayos clínicos sobre AA4500
-
Endo PharmaceuticalsTerminadoEnfermedad de PeyronieEstados Unidos
-
Endo PharmaceuticalsTerminadoEnfermedad de PeyronieEstados Unidos, Dinamarca, Francia, Alemania, Italia, Nueva Zelanda, España, Suecia, Reino Unido
-
Endo PharmaceuticalsTerminadoEnfermedad de PeyronieEstados Unidos, Australia
-
Endo PharmaceuticalsTerminadoEnfermedad de PeyronieEstados Unidos, Australia
-
Endo PharmaceuticalsTerminadoA Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's ContractureContractura de DupuytrenEstados Unidos
-
Endo PharmaceuticalsTerminado
-
Endo PharmaceuticalsTerminadoEnfermedad de PeyronieEstados Unidos
-
Endo PharmaceuticalsTerminado
-
Endo PharmaceuticalsTerminadoEnfermedad de Dupuytren avanzadaAustralia
-
Endo PharmaceuticalsTerminadoEnfermedad de Dupuytren avanzadaEstados Unidos